Moreover, in a variety of cancers, including colorectal, prostate, and liver cancers, GLS1 has been reported to be abnormally highly expressed in tumor cells in comparison with the normal adjacent tissues [35–37], and some studies have even suggested that GLS1 may serve as a novel biomarker for the pathological diagnosis and prognosis of hepatocellular carcinoma [35]. This evidence concerns the gene GLS and neoplasm.